+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020

  • PDF Icon

    Report

  • 314 Pages
  • November 2020
  • Region: Global
  • GlobalData
  • ID: 5212223
Summary

The publisher's Medical Devices sector report, “Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Inborn Gene or Chromosome Alterations Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Inborn Gene or Chromosome Alterations Tests are the genetic tests used to detect monogenetic disorders (like Cystic Fibrosis, Haemochromatosis, Prothrombin Mutation etc), polygenetic disorders (like Asthma , Atherosclerosis, Diabetes, Hypertension, Osteoporosis, etc), chromosomal disorders (like Down's Syndrome, Edwards Syndrome etc), polymorphisms (like HLA-Typing etc).

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Inborn Gene or Chromosome Alterations Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inborn Gene or Chromosome Alterations Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inborn Gene or Chromosome Alterations Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.1 Inborn Gene or Chromosome Alterations Overview
3 Products under Development
3.1 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
3.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
3.3 Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
3.4 Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
3.5 Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials
4 Inborn Gene or Chromosome Alterations - Pipeline Products under Development by Companies
4.1 Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
4.2 Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
5 Inborn Gene or Chromosome Alterations Companies and Product Overview6 Inborn Gene or Chromosome Alterations- Recent Developments
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer
List of Tables
Table 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
Table 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
Table 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
Table 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
Table 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials
Table 6: Inborn Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
Table 7: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
Table 8: Aarhus University Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Cystic Fibrosis Urine Test - Product Status
Table 10: Cystic Fibrosis Urine Test - Product Description
Table 11: AbaStar MDx Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Molecular Diagnostic Test - Bipolar Disorder - Product Status
Table 13: Molecular Diagnostic Test - Bipolar Disorder - Product Description
Table 14: Molecular Diagnostic Test - Depression - Product Status
Table 15: Molecular Diagnostic Test - Depression - Product Description
Table 16: Molecular Diagnostic Test - Parkinson's Disease - Product Status
Table 17: Molecular Diagnostic Test - Parkinson's Disease - Product Description
Table 18: Molecular Diagnostic Test - Schizophrenia - Product Status
Table 19: Molecular Diagnostic Test - Schizophrenia - Product Description
Table 20: AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Diagnostic Test - Hereditary Deafness - Product Status
Table 22: Diagnostic Test - Hereditary Deafness - Product Description
Table 23: Agena Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Sensigene Trisomy 21 Laboratory Developed Test - Product Status
Table 25: Sensigene Trisomy 21 Laboratory Developed Test - Product Description
Table 26: Alexion Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: SmartPanel - Product Status
Table 28: SmartPanel - Product Description
Table 29: Allele Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 30: RAD4CHD Test - Product Status
Table 31: RAD4CHD Test - Product Description
Table 32: Amarantus Bioscience Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Diagnostic Test - IFN-Beta Resistance - Product Status
Table 34: Diagnostic Test - IFN-Beta Resistance - Product Description
Table 35: Amity University Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Prenatal Screening Kit - Product Status
Table 37: Prenatal Screening Kit - Product Description
Table 38: Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 39: PDx Pre-Symptomatic Test - Product Status
Table 40: PDx Pre-Symptomatic Test - Product Description
Table 41: Asuragen Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 42: Signature CF Expand - Product Status
Table 43: Signature CF Expand - Product Description
Table 44: Augusta University Pipeline Products & Ongoing Clinical Trials Overview
Table 45: SUMO Gene Test - Type 1 Diabetes - Product Status
Table 46: SUMO Gene Test - Type 1 Diabetes - Product Description
Table 47: AutoGenomics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 48: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Status
Table 49: DNA Guided Diagnostic Test - Cardiovascular Disease - Product Description
Table 50: DNA Guided Diagnostic Test - Diabetes - Product Status
Table 51: DNA Guided Diagnostic Test - Diabetes - Product Description
Table 52: DNA Guided Diagnostic Test - Obesity - Product Status
Table 53: DNA Guided Diagnostic Test - Obesity - Product Description
Table 54: INFINITI Neural Response Panel - Product Status
List of Figures
Figure 1: Inborn Gene or Chromosome Alterations - Pipeline Products by Stage of Development
Figure 2: Inborn Gene or Chromosome Alterations - Pipeline Products by Territory
Figure 3: Inborn Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
Figure 4: Inborn Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
Figure 5: Inborn Gene or Chromosome Alterations - Ongoing Clinical Trials

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aarhus University
  • AbaStar MDx Inc
  • AC-Gen Reading Life S.L.
  • Agena Bioscience Inc
  • Alexion Pharmaceuticals Inc
  • Allele Diagnostics Inc
  • Amarantus Bioscience Holdings Inc
  • Amity University
  • Arrayit Corporation
  • Asuragen Inc
  • Augusta University
  • AutoGenomics Inc
  • Baylor College of Medicine
  • BioCeps (Inactive)
  • Biocept Inc
  • Biofidelity Ltd
  • Boston Children's Hospital
  • Cardiff Oncology Inc
  • CareDx Inc
  • Celula Inc
  • Children's Hospital of Philadelphia
  • China Medical Technologies Inc (Inactive)
  • ChipCare Corp
  • ChromaCode Inc
  • Chronix Biomedical Inc
  • Cincinnati Children's Hospital Medical Center
  • Columbia University
  • Consejo Superior de Investigaciones Cientificas
  • Daan Gene Co Ltd
  • Decipher GenX, Inc.
  • Duke University
  • Echelon Diagnostics Inc
  • EGIS Pharmaceuticals Plc
  • Eone Diagnomics Genome Center Co Ltd
  • Epinex Diagnostics Inc
  • Fina Biotech SL
  • Firalis SAS
  • Fluidigm Corp
  • Fraunhofer Institute for Cell Therapy and Immunology
  • Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV
  • Fred Hutchinson Cancer Research Center
  • French National Institute of Health and Medical Research
  • genedrive plc
  • Genentech USA Inc
  • Genisphere LLC
  • Genomic Vision SA
  • genomiQa Pty Ltd
  • German Cancer Research Center
  • German Institute of Human Nutrition
  • Gilupi GmbH
  • GnuBIO Inc
  • Hadassah Medical Center
  • Hebrew University of Jerusalem
  • Helicos BioSciences Corporation
  • Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
  • Hummingbird Diagnostics GmbH
  • iGene Laboratory Pte Ltd
  • Illumina Inc
  • Indiana University
  • Interpace Biosciences Inc
  • iXlayer Inc
  • Johns Hopkins University
  • JS Genetics Inc
  • Juneau Biosciences LLC
  • KellBenx Inc (Inactive)
  • Laboratory Corp of America Holdings
  • Laval University
  • LifeCodexx AG
  • LineaGen Inc
  • Lucid Diagnostics Inc
  • Maastricht University Medical Center
  • Massachusetts Eye and Ear Infirmary
  • Max Delbruck Center for Molecular Medicine
  • McGill University
  • Medical Research Council
  • MeMed Diagnostics LTD
  • Myriad Genetics Inc
  • Nanosphere Inc
  • National Jewish Health
  • National University of Singapore
  • Nel ASA
  • NewGene Ltd
  • NIPD Genetics
  • Oxford Biodynamics Plc
  • Oxford Gene Technology Ltd
  • ParagonDx LLC (Inactive)
  • PerkinElmer Inc
  • Population Bio Inc
  • Precipio Inc
  • PreCyte, Inc.
  • PredictImmune Ltd
  • Predictive Therapeutics LLC
  • Predigen Inc
  • Progenity Inc
  • Proove BioScience Inc
  • Quest Diagnostics Inc
  • Roche Diagnostics International Ltd
  • Sapien Biosciences
  • Scipher Medicine Corp
  • Seattle Children's Hospital
  • Seegene Inc
  • Sequenom Inc
  • Sheba Medical Center
  • SkylineDx BV
  • Sophia Genetics SA
  • StellarGene Technologies Pvt Ltd
  • Strand Life Sciences Pvt Ltd
  • SUNY Upstate Medical University
  • Takeda Pharmaceuticals International AG
  • TAmiRNA GmbH
  • TBG Diagnostics Ltd
  • Tel Aviv University
  • The Francis Crick Institute Ltd
  • thromboDx
  • Transplant Genomics Inc
  • Tufts Medical Center
  • University Hospital of Cologne
  • University of Arizona
  • University of California San Diego
  • University of California San Francisco
  • University of Cambridge
  • University of Cape Town
  • University of Central Florida
  • University of Colorado
  • University of Illinois at Chicago
  • University of Melbourne
  • University of Michigan
  • University of Oxford
  • University of Pennsylvania
  • University of Pittsburgh
  • University of Turku
  • Vanadis Diagnostics AB
  • Vanderbilt University
  • Vanessa Research Inc
  • Virginia Commonwealth University
  • VitaPath Genetics, Inc.
  • Yale University